Using bevacizumab with different chemotherapeutic regimens in metastatic colorectal cancer: Balancing utility with low toxicity

Therapeutic Advances in Medical Oncology

Volumn 2, Issue 5, 2010, Pages 309-317

  Chong, G ^a   Tebbutt, N C ^a  

^a AUSTIN HEALTH   (Australia)

Author keywords

bevacizumab; colorectal cancer; overall survival; progression free survival; tolerability

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MITOMYCIN C; OXALIPLATIN; PANITUMUMAB; PLACEBO; VASCULOTROPIN;

BLEEDING; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG DOSE REGIMEN; DRUG EFFICACY; HAND FOOT SYNDROME; HEADACHE; HUMAN; HYPERTENSION; LIVER METASTASIS; METASTASIS; NEUROPATHY; OVERALL SURVIVAL; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; REVIEW; SKIN TOXICITY; TREATMENT DURATION; VENOUS THROMBOEMBOLISM; WOUND HEALING IMPAIRMENT;

EID: 78649302303     PISSN: 17588340     EISSN: None     Source Type: Journal    
DOI: 10.1177/1758834010375096     Document Type: Review

References (37)

1. Adam, R., Avisar, E., Ariche, A., Giachetti, S., Azoulay, D., Castaing, D. et al. (2001) Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol 8: 347-353.
2. Adam, R., Wicherts, D.A., de Haas, R.J., Ciacio, O., Levi, F., Paule, B. et al. (2009) Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol 27: 1829-1835.
3. Chen, H.X., Mooney, M., Boron, M., Vena, D., Mosby, K., Grochow, L. et al. (2006) Phase II multi-center trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301. J Clin Oncol 24: 3354-3360.
4. Cunningham, D. and Glimelius, B. ( 1999) A phase III study of irinotecan (CPT-11) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy. V 301 Study Group. Semin Oncol 26(1 Suppl 5): 6-12.
5. de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J. et al. (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938-2947.
6. Ellis, L.M. ( 2006) Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer. Semin Oncol 33(5 Suppl 10): S1-S7.
7. Fuchs, C.S., Marshall, J. and Barrueco, J. ( 2008) Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. J Clin Oncol 26: 689-690.
8. Fuchs, C.S., Marshall, J., Mitchell, E., Wierzbicki, R., Ganju, V., Jeffery, M. et al. (2007) Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 25: 4779-4786.
9. Giantonio, B.J., Catalano, P.J., Meropol, N.J., O'Dwyer, P.J., Mitchell, E.P., Alberts, S.R. et al. (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25: 1539-1544.
10. Giantonio, B.J., Levy, D.E., O'Dwyer, P.J., Meropol, N.J., Catalano, P.J. and Benson III, A.B. ( 2006) A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200. Ann Oncol 17: 1399-1403.
11. Glusker, P., Recht, L. and Lane, B. ( 2006) Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 354: 980-982; discussion 980-982.
12. Gordon, M.S., Margolin, K., Talpaz, M., Sledge Jr, G.W., Holmgren, E., Benjamin, R. et al. (2001) Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19: 843-850.
13. Grothey, A., Hedrick, E.E., Mass, R.D., Sarkar, S., Suzuki, S., Ramanathan, R.K. et al. (2008 a) Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N 9741 and AVF2107. J Clin Oncol 26: 183-189.
14. Grothey, A., Sugrue, M.M., Purdie, D.M., Dong, W., Sargent, D., Hedrick, E. et al. (2008 b) Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 26: 5326-5334.
15. Gruenberger, B., Tamandl, D., Schueller, J., Scheithauer, W., Zielinski, C., Herbst, F. et al. (2008) Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 26: 1830-1835.
16. Hapani, S., Chu, D. and Wu, S. (2009) Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol 10: 559-568.
17. Hecht, J.R., Mitchell, E., Chidiac, T., Scroggin, C., Hagenstad, C., Spigel, D. et al. (2009) A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 27: 672-680.
18. Hochster, H.S., Hart, L.L., Ramanathan, R.K., Childs, B.H., Hainsworth, J.D., Cohn, A.L. et al. (2008) Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol 26: 3523-3529.
19. Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W. et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342.
20. Hurwitz, H.I., Yi, J., Ince, W., Novotny, W.F. and Rosen, O. (2009) The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. Oncologist 14: 22-28.
21. Kabbinavar, F., Hurwitz, H.I., Fehrenbacher, L., Meropol, N.J., Novotny, W.F., Lieberman, G. et al. (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU / LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21: 60-65.
22. Kabbinavar, F.F., Schulz, J., McCleod, M., Patel, T., Hamm, J.T., Hecht, J.R. et al. (2005) Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 23: 3697-3705.
23. Kabbinavar, F.F., Wallace, J.F., Holmgren, E., Yi, J., Cella, D., Yost, K.J. et al. (2008) Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer. Oncologist 13: 1021-1029.
24. Kim, K.J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H.S. et al. (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362: 841-844.
25. Klinger, M., Eipeldauer, S., Hacker, S., Herberger, B., Tamandl, D., Dorfmeister, M. et al. (2009) Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX / FOLFOX therapy of colorectal cancer liver metastases. Eur J Surg Oncol 35: 515-520.
26. Kopetz, S., Hoff, P.M., Morris, J.S., Wolff, R.A., Eng, C., Glover, K.Y. et al. (2010) Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol 28: 453-459.
27. Kozloff, M., Yood, M.U., Berlin, J., Flynn, P.J., Kabbinavar, F.F., Purdie, D.M. et al. (2009) Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist 14: 862-870.
28. Nordlinger, B., Sorbye, H., Glimelius, B., Poston, G.J., Schlag, P.M., Rougier, P. et al. (2008) Perioperative chemotherapy with FOLFOX 4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371: 1007-1016.
29. Ribero, D., Wang, H., Donadon, M., Zorzi, D., Thomas, M.B., Eng, C. et al. (2007) Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 110: 2761-2767.
30. Saltz, L.B., Clarke, S., Diaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R. et al. (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26: 2013-2019.
31. Saltz, L.B., Lenz, H.J., Kindler, H.L., Hochster, H.S., Wadler, S., Hoff, P.M. et al. (2007) Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol 25: 4557-4561.
32. Scappaticci, F.A., Skillings, J.R., Holden, S.N., Gerber, H.P., Miller, K., Kabbinavar, F. et al. (2007) Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99: 1232-1239.
33. Tebbutt, N.C., Wilson, K., Gebski, V.J., Cummins, M.M., Zannino, D., van Hazel, G.A. et al. (2010) Capecitabine, bevacizumab and mitomycin C in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group randomised phase III MAX study. J Clin Oncol, in press.
34. Tol, J., Koopman, M., Cats, A., Rodenburg, C.J., Creemers, G.J., Schrama, J.G. et al. (2009) Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360: 563-572.
35. van Cutsem, E., Rivera, F., Berry, S., Kretzschmar, A., Michael, M., DiBartolomeo, M. et al. (2009) Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 20: 1842-1847.
36. Warren, R.S., Yuan, H., Matli, M.R., Gillett, N.A. and Ferrara, N. ( 1995) Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 95: 1789-1797.
37. Welch, S., Spithoff, K., Rumble, R.B. and Maroun, J. (2010) Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review. Ann Oncol 21: 1152-1162.